Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ: HRMY )

34.06 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Harmony Biosciences
Via GlobeNewswire
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024
Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently. 
Via InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024
Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks. 
Via InvestorPlace
NASDAQ:HRMY: good value for what you're paying.
In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
NASDAQ:HRMY stands out as a growth opportunity that won't break the bank.
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY. 
Via Chartmill
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 6 Analysts
Via Benzinga
Harmony Biosciences's Earnings Outlook
Via Benzinga
Analyst Ratings for Harmony Biosciences
Via Benzinga
Investors should take notice of NASDAQ:HRMY—it offers a great deal for the fundamentals it presents.
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Why Harmony Biosciences Stock Got Slammed Today
The commercial-stage company was dinged by a bearish new take from a researcher. 
Via The Motley Fool
2023 Year In Review
The S&P 500 had a strong year in 2023, returning about 24% to investors from the beginning of the year to the end. Some of that was a bounce back from a poor 2022 when it was down over 11%. 
Via Talk Markets
Topics Stocks
Exposures US Equities
NASDAQ:HRMY is showing good growth, while it is not too expensive.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside. 
Via InvestorPlace
NASDAQ:HRMY, an undervalued stock with good fundamentals.
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
Russell 2000 Front-Runners: 3 Stocks to Keep an Eye On
Although Russell 2000 stocks may operate in the lightweight category, these entities could potentially provide a knockout punch. 
Via InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY.
Investors seeking growth at a reasonable cost should explore HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY). 
Via Chartmill
NASDAQ:HRMY is probably undervalued for the fundamentals it is displaying.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable.
Investors should take note ofHARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), a growth stock that remains attractively priced. 
Via Chartmill
Quick Look At Reports From ServiceNow, Chipotle, And Harmony
ServiceNow is a steady, reliable SaaS firm that continues to prove its value and growth potential to investors. 
Via Talk Markets
NASDAQ:HRMY is an undervalued gem with solid fundamentals.
For those who appreciate value investing, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a compelling option with its solid fundamentals. 
Via Chartmill
Harmony Biosciences (HRMY) Q3 2023 Earnings Call Transcript
HRMY earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
From Harmony Biosciences
Via GlobeNewswire
Why Harmony Biosciences Stock Is Trading Higher Today
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) shares are trading higher on Monday as the stock rebounds after falling Friday on Phase 3 INTU 
Via Benzinga
Nasdaq Down Over 1%; Wells Fargo Beats Expectations
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 1% on Friday. The Dow traded down 0.02% to 33,622.97 while the NASDAQ fell 1.27% to 13,401.56. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Stocks Mixed Amid Earnings, Consumer Sentiment Data
Stocks are mixed this afternoon, as investors unpack earnings reports from several bank giants as well as economic data. 
Via Talk Markets
Why Belden Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc. 
Via Benzinga
Why Shares of Harmony Bioscience Are Falling on Friday
The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.